Summary
Amgen Inc. announced significant changes in its executive leadership team through an 8-K filing on July 26, 2018. The report details the retirements of two key Executive Vice Presidents: Sean E. Harper from Research and Development and Anthony C. Hooper from Global Commercial Operations. These departures mark the end of long tenures for experienced leaders, with both individuals agreeing to stay on in non-executive capacities to ensure smooth transitions. To fill these critical roles, Amgen has appointed David M. Reese as the new Executive Vice President of Research and Development, moving from his previous position as Senior Vice President of Translational Sciences and Oncology. Additionally, Murdo Gordon, formerly Chief Commercial Officer at Bristol-Myers Squibb Company, has been appointed as the new Executive Vice President of Global Commercial Operations. These appointments signal a strategic transition in leadership for two core areas of Amgen's operations.
Key Highlights
- 1Retirement of Sean E. Harper, Executive Vice President of Research and Development, effective July 26, 2018.
- 2Sean E. Harper will remain with Amgen in a non-executive role to assist with R&D transition until the end of 2018.
- 3Appointment of David M. Reese as the new Executive Vice President of Research and Development, effective July 26, 2018.
- 4Retirement of Anthony C. Hooper, Executive Vice President of Global Commercial Operations, effective September 3, 2018.
- 5Anthony C. Hooper will remain with Amgen in a non-executive role to assist with Global Commercial Operations transition through 2019.
- 6Appointment of Murdo Gordon as the new Executive Vice President of Global Commercial Operations, effective September 3, 2018.
- 7Murdo Gordon joins Amgen from Bristol-Myers Squibb Company where he served as Chief Commercial Officer.